Commonly asked questions

It's normal, even expected, for you to have questions before starting treatment. Click below to see answers to the most commonly asked questions about FYARRO. Consult with your doctor to make sure that this guidance meets the needs of your individual treatment journey.

PEComa patient portrayal

Commonly asked questions

It's normal, even expected, for you to have questions before starting treatment. Click below to see answers to the most commonly asked questions about FYARRO. Consult with your doctor to make sure that this guidance meets the needs of your individual treatment journey.

PEComa patient portrayal PEComa patient portrayal

While there is no set diet or exercise plan for people living with advanced malignant PEComa, there may be things you can do to maintain a healthy lifestyle during your treatment. Talk to your doctor about nutrition and exercise advice. Your treatment center may have a nutritionist on staff whom you can work with.

Some people may find it helpful to stay active during treatment. Discuss with your doctor how you are feeling so that, together, you can come up with an exercise routine that is best suited for you.

Avoid grapefruit and grapefruit juice while taking FYARRO. Talk to your doctor about any herbal supplements that you currently take or are considering taking as they may interact with FYARRO treatment.

Each FYARRO treatment cycle is 3 weeks, which means treatment cycles repeat every 21 days. Doses are given once a week for 2 weeks, on Day 1 and Day 8, followed by 1 week off.

While there are no data on how FYARRO impacts fertility, based on studies in animals and the way FYARRO works, male and female fertility may be affected by treatment with FYARRO. Talk to your doctor if you have specific concerns about fertility.

Certain medications, vitamins, and herbal supplements may interact with FYARRO treatment. Make sure to tell your doctor about all the medications (prescription and over the counter), vitamins, and herbal supplements that you are currently taking before starting FYARRO and they can let you know which ones you can and cannot take during treatment with FYARRO.

You should not receive a live vaccine or be around people who have recently received a live vaccine during your treatment with FYARRO. If you are not sure about the type of vaccine, ask your doctor. Vaccinations may be less effective while being treated with FYARRO.

There are organizations created for people living with cancer, including PEComa:

  • Sarcoma Foundation of America (curesarcoma.org) advocates for sarcoma patients through funding research and raising awareness about this rare cancer

  • Sarcoma Alliance (sarcomaalliance.org) helps patients and their loved ones connect with others living with sarcoma and find trustworthy information

  • American Cancer Society (cancer.org) funds and conducts research while also supporting patients by sharing expert advice on living with cancer

  • National Organization for Rare Disorders (NORD) (rarediseases.org) is an advocacy organization for people with rare disease as well as the organizations that support them. With 300 organization members, NORD is committed to serving patients and furthering research in rare diseases

AadiAssist provides support services for patients taking FYARRO. Learn more about AadiAssist here.

FYARRO Patient Brochure

Made for me

Get support through your treatment journey. Access
helpful resources that were made just for you.

Made for me

Get support through your treatment journey. Access helpful resources that were made just for you.

*FYARRO is not for everyone. Talk to your doctor to see if FYARRO may be right for you.

INDICATION

FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) is a prescription medicine used to treat adults with malignant perivascular epithelioid cell tumors (PEComa) that have spread to other parts of the body (metastatic) or cannot be removed by surgery (locally advanced, unresectable). It is not known if FYARRO is safe and effective in people with severe liver problems or in children.

IMPORTANT SAFETY INFORMATION

Do not use FYARRO if you have had a severe allergic reaction to sirolimus or other medications that work similarly to sirolimus (eg, everolimus, temsirolimus), or human albumin.

FYARRO can cause the following serious side effects; depending on the severity, your doctor may decide to decrease your dose or stop treatment with FYARRO:

  • Mouth ulcers and sores are common during treatment with FYARRO and can be severe. If you develop pain, discomfort, or open sores in your mouth, tell your doctor.
  • Decreased blood cell counts (red blood cells, platelets, and white blood cells). Your doctor should do blood tests before you start and during treatment with FYARRO.
  • Infections. FYARRO can make you more susceptible to infections. Tell your doctor right away if you develop a fever, chills, or do not feel well.
  • Low potassium, which can affect your heart rhythm if severe. Your doctor should do blood tests to check your potassium levels before you start and during treatment with FYARRO.
  • Increased blood sugar levels in blood. Your doctor should do blood tests before you start and during treatment with FYARRO. Diabetic patients should monitor their blood sugar more frequently.
  • Lung inflammation. If you develop a persistent cough, chest pain, or shortness of breath, tell your doctor right away.
  • Bleeding, which can lead to death. If you develop bleeding, tell your doctor right away.
  • Allergic reactions, which can be severe and life-threatening. Tell your doctor or get medical help right away if you develop swelling of your face, lips, tongue, or throat; a rash, itching, or flushing of your skin; hives; difficulty breathing or swallowing; chest pain; or dizziness.
  • Harm to an unborn baby. Tell your doctor right away if you become pregnant or think you might be pregnant during treatment with FYARRO. Exposure to FYARRO during pregnancy or within 12 weeks before becoming pregnant can cause harm to your baby. If you are able to become pregnant, your doctor should do a pregnancy test before you start treatment with FYARRO. Birth control should be used while receiving FYARRO and for 12 weeks after your last dose of FYARRO. Men with a female partner should use effective birth control during treatment and for 12 weeks after the last dose of FYARRO.
  • Infertility in woman and men. FYARRO may affect your ability to become pregnant if you are female, or your ability to father a child if you are male.
  • Vaccinations may be less effective while being treated with FYARRO. In addition, you should not receive a live vaccine or be around people who have recently received a live vaccine during your treatment with FYARRO.

Before taking FYARRO, tell your doctor if you are breast feeding. It is not known if FYARRO could pass into breast milk and harm your baby. You should not breast feed during treatment with FYARRO and for 2 weeks after the last dose. Tell your doctor about all your medical conditions and the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Using FYARRO with certain other medicines can cause serious side effects. Tell your doctor before you start taking any new medicine. You should not drink grapefruit juice or eat grapefruit during your treatment with FYARRO. It may make the amount of FYARRO in your blood increase to a harmful level.

The most common side effects with FYARRO include the following: mouth ulcers or sores; feeling weak or tired; rash; infection; nausea; swelling of arms, hands, feet, ankles, face, or other parts of the body; diarrhea; body pain; decreased weight and appetite; cough; vomiting; and altered taste.

These are not all the possible side effects of FYARRO. Tell your doctor if you have any side effect that bothers you or does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information.

INDICATION

FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) is a prescription medicine used to treat adults with malignant perivascular epithelioid cell tumors (PEComa) that have spread to other parts of the body (metastatic) or cannot be removed by surgery (locally advanced, unresectable). It is not known if FYARRO is safe and effective in people with severe liver problems or in children.

INDICATION
IMPORTANT SAFETY INFORMATION

Do not use FYARRO if you have had a severe allergic reaction to sirolimus or other medications that work similarly to sirolimus (eg, everolimus, temsirolimus), or human albumin.

FYARRO can cause the following serious side effects; depending on the severity, your doctor may decide to decrease your dose or stop treatment with FYARRO:

  • Mouth ulcers and sores are common during treatment with FYARRO and can be severe. If you develop pain, discomfort, or open sores in your mouth, tell your doctor.
  • Decreased blood cell counts (red blood cells, platelets, and white blood cells). Your doctor should do blood tests before you start and during treatment with FYARRO.
  • Infections. FYARRO can make you more susceptible to infections. Tell your doctor right away if you develop a fever, chills, or do not feel well.
  • Low potassium, which can affect your heart rhythm if severe. Your doctor should do blood tests to check your potassium levels before you start and during treatment with FYARRO.
  • Increased blood sugar levels in blood. Your doctor should do blood tests before you start and during treatment with FYARRO. Diabetic patients should monitor their blood sugar more frequently.
  • Lung inflammation. If you develop a persistent cough, chest pain, or shortness of breath, tell your doctor right away.
  • Bleeding, which can lead to death. If you develop bleeding, tell your doctor right away.
  • Allergic reactions, which can be severe and life-threatening. Tell your doctor or get medical help right away if you develop swelling of your face, lips, tongue, or throat; a rash, itching, or flushing of your skin; hives; difficulty breathing or swallowing; chest pain; or dizziness.
  • Harm to an unborn baby. Tell your doctor right away if you become pregnant or think you might be pregnant during treatment with FYARRO. Exposure to FYARRO during pregnancy or within 12 weeks before becoming pregnant can cause harm to your baby. If you are able to become pregnant, your doctor should do a pregnancy test before you start treatment with FYARRO. Birth control should be used while receiving FYARRO and for 12 weeks after your last dose of FYARRO. Men with a female partner should use effective birth control during treatment and for 12 weeks after the last dose of FYARRO.
  • Infertility in woman and men. FYARRO may affect your ability to become pregnant if you are female, or your ability to father a child if you are male.
  • Vaccinations may be less effective while being treated with FYARRO. In addition, you should not receive a live vaccine or be around people who have recently received a live vaccine during your treatment with FYARRO.

Before taking FYARRO, tell your doctor if you are breast feeding. It is not known if FYARRO could pass into breast milk and harm your baby. You should not breast feed during treatment with FYARRO and for 2 weeks after the last dose. Tell your doctor about all your medical conditions and the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Using FYARRO with certain other medicines can cause serious side effects. Tell your doctor before you start taking any new medicine. You should not drink grapefruit juice or eat grapefruit during your treatment with FYARRO. It may make the amount of FYARRO in your blood increase to a harmful level.

The most common side effects with FYARRO include the following: mouth ulcers or sores; feeling weak or tired; rash; infection; nausea; swelling of arms, hands, feet, ankles, face, or other parts of the body; diarrhea; body pain; decreased weight and appetite; cough; vomiting; and altered taste.

These are not all the possible side effects of FYARRO. Tell your doctor if you have any side effect that bothers you or does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATION

FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) is a prescription medicine used to treat adults with malignant perivascular epithelioid cell tumors (PEComa) that have spread to other parts of the body (metastatic) or cannot be removed by surgery (locally advanced, unresectable). It is not known if FYARRO is safe and effective in people with severe liver problems or in children.